In both pivotal trials, a statistically significant greater percentage of treatment patients experienced clinical response vs those treated with placebo at 21 to 30 days following a single dose.
SCY-078 is an investigational antifungal agent that is a semi-synthetic derivative of the natural product enfumafungin.
The majority of syphilis infections are seen particularly in gay, bisexual, and other men who have sex with men (MSM), of which half are also diagnosed with HIV.
The approval was based on two randomized, placebo-controlled studies which evaluated the efficacy of Solosec in the treatment of bacterial vaginosis.
Gonorrhea is a sexually transmitted infection (STI) that can affect the genitals, rectum, and throat. Complications include pelvic inflammatory disease, ectopic pregnancy, infertility, and an increased risk of HIV.
The FDA has accepted and granted Priority Review to the New Drug Application (NDA) of Solosec (secnidazole oral granules; Symbiomix) for the treatment of bacterial vaginosis (BV).
Symbiomix announced the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Solosec (secnidazole oral granules) for the treatment of bacterial vaginosis (BV).
Data from a randomized, double-blind clinical study found that the use of pritelivir led to a lower percentage of swabs with herpes simplex virus (HSV) detection over 28 days vs. valacyclovir. Full findings from the study are published in JAMA.
For pregnant women, probiotics have no effect on vaginal health, according to a study published in the November issue of the American Journal of Obstetrics & Gynecology.
BD announced that the Food and Drug Administration (FDA) has granted marketing clearance for BD MAX Vaginal Panel to detect the most common causes for vaginitis.
Symbiomix announced positive results from the second pivotal Phase 3 trial of SYM-1219 (secnidazole) for the treatment of bacterial vaginosis (BV).
The number of hepatitis C-linked deaths in the United States reached a record high in 2014, and the disease is now the leading cause of infectious disease mortality in the United States.
The Food and Drug Administration (FDA) has granted SYM-1219 (secnidazole, Symbiomix) Fast Track designation for the treatment of bacterial vaginosis (BV).
A major change in Papanicolaou (Pap) test guidelines introduced in 2009 may have had an unintended consequence: Some young women are missing out on screening for chlamydia.
New recommendations have been provided to update the 2010 guidelines on the treatment and management of sexually transmitted diseases (STDs).
For urban women ages 25 years and older, the prevalence of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) is low, and women may be overscreened.
The Centers for Disease Control and Prevention (CDC) has released its annual fact sheet of the three reported sexually transmitted diseases (STDs): chlamydia, gonorrhea, and syphilis.
Monistat announced the launch of Monistat Complete Care products, which include a vaginal health test, probiotics, and an odor-neutralizing gel.
A new study has found that 69% percent of healthy American adults are infected with one or more of 109 strains of the human papillomavirus (HPV).
e.p.t. announced the launch of its Preconception Health Test, a new test that measures vaginal acidity and indicates the presence of infections so women can seek treatment before trying to conceive.
Actavis and Valeant announced that the FDA has approved Metronidazole 1.3% Vaginal Gel for the treatment of bacterial vaginosis.